- Home
- LPCN vs MIRA Comparison
LPCN vs MIRA Comparison
Compare LPCN & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPCN | MIRA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 50.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LPCN | MIRA |
|---|---|---|
| Price | $8.83 | $1.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 109.4K | ★ 156.7K |
| Earning Date | 03-12-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,322,693.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.52 | $0.73 |
| 52 Week High | $12.37 | $2.45 |
Technical Indicators
Market Signals| Indicator | LPCN | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 32.92 |
| Support Level | $8.35 | $1.16 |
| Resistance Level | $9.15 | $1.25 |
| Average True Range (ATR) | 0.73 | 0.07 |
| MACD | -0.23 | -0.00 |
| Stochastic Oscillator | 33.29 | 15.38 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.